PL378214A1 - Pochodne karbostyrylu i inhibitory wychwytu zwrotnego serotoniny do leczenia zaburzeń nastroju - Google Patents

Pochodne karbostyrylu i inhibitory wychwytu zwrotnego serotoniny do leczenia zaburzeń nastroju

Info

Publication number: PL378214A1
Authority: PL; Poland
Prior art keywords: serotonin reuptake; mood disorders; treatment; reuptake inhibitors; carbostyril derivatives
Prior art date: 2002-12-27

Application number

PL378214A

Other languages

English (en)

Other versions

PL211975B1 (pl

Inventor

Tetsuro Kikuchi

Taro Iwamoto

Tsuyoshi Hirose

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-27

Filing date

2003-12-25

Publication date

2006-03-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32716306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL378214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-12-25 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2006-03-20 Publication of PL378214A1 publication Critical patent/PL378214A1/pl

2012-07-31 Publication of PL211975B1 publication Critical patent/PL211975B1/pl

Links

LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title abstract 3
239000003772 serotonin uptake inhibitor Substances 0.000 title abstract 3
208000019022 Mood disease Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 1
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 abstract 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 abstract 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 abstract 1
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 1
229960004372 aripiprazole Drugs 0.000 abstract 1
229960001653 citalopram Drugs 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
229960002866 duloxetine Drugs 0.000 abstract 1
229960004341 escitalopram Drugs 0.000 abstract 1
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 abstract 1
229960002464 fluoxetine Drugs 0.000 abstract 1
229960004038 fluvoxamine Drugs 0.000 abstract 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 abstract 1
208000024714 major depressive disease Diseases 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
229960000600 milnacipran Drugs 0.000 abstract 1
229960002296 paroxetine Drugs 0.000 abstract 1
229940076279 serotonin Drugs 0.000 abstract 1
229960002073 sertraline Drugs 0.000 abstract 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 abstract 1
229960004688 venlafaxine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

PL378214A 2002-12-27 2003-12-25 Kompozycja farmaceutyczna zawierająca pochodną karbostyrylu i inhibitor wychwytu zwrotnego serotoniny oraz jej zastosowanie do leczenia zaburzeń nastroju PL211975B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002379003		2002-12-27
US47048103P	2003-05-14	2003-05-14

Publications (2)

Publication Number	Publication Date
PL378214A1 true PL378214A1 (pl)	2006-03-20
PL211975B1 PL211975B1 (pl)	2012-07-31

Family

ID=32716306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL378214A PL211975B1 (pl)	2002-12-27	2003-12-25	Kompozycja farmaceutyczna zawierająca pochodną karbostyrylu i inhibitor wychwytu zwrotnego serotoniny oraz jej zastosowanie do leczenia zaburzeń nastroju

Country Status (26)

Country	Link
US (5)	US9387182B2 (pl)
EP (2)	EP1723957A3 (pl)
JP (1)	JP4284524B2 (pl)
KR (2)	KR100858852B1 (pl)
CN (2)	CN1726039B (pl)
AT (1)	ATE376419T1 (pl)
AU (1)	AU2003295235B2 (pl)
BR (1)	BR0317771A (pl)
CA (1)	CA2511619C (pl)
CY (1)	CY1108060T1 (pl)
DE (1)	DE60317098T2 (pl)
DK (1)	DK1575590T3 (pl)
EC (1)	ECSP055885A (pl)
ES (1)	ES2295677T3 (pl)
IL (1)	IL169358A (pl)
MX (1)	MXPA05006857A (pl)
MY (1)	MY152919A (pl)
NO (1)	NO333291B1 (pl)
NZ (2)	NZ556779A (pl)
PE (1)	PE20040923A1 (pl)
PL (1)	PL211975B1 (pl)
PT (1)	PT1575590E (pl)
RU (2)	RU2356554C2 (pl)
SI (1)	SI1575590T1 (pl)
WO (1)	WO2004060374A1 (pl)
ZA (1)	ZA200503873B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05012538A (es) *	2003-05-23	2006-02-22	Otsuka Pharma Co Ltd	Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo.
EP1797039A1 (en) *	2004-09-13	2007-06-20	Matrix Laboratories Ltd	Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
KR20070083826A (ko)	2004-10-28	2007-08-24	에스케이 주식회사	우울증을 위한 부가 요법
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
GB2456183A (en)	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JOP20120083B1 (ar) *	2011-04-05	2021-08-17	Otsuka Pharma Co Ltd	توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JO3227B1 (ar)	2011-09-08	2018-03-08	Otsuka Pharma Co Ltd	مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
WO2014002553A1 (ja)	2012-06-29	2014-01-03	丸石製薬株式会社	アリピプラゾールの経口医薬製剤
GB2542155B (en)	2015-09-09	2018-08-01	Gw Pharma Ltd	Use of cannabidiol in the treatment of mental disorders
CN111455019A (zh) *	2018-05-03	2020-07-28	杭州端丽生物技术有限公司	化合物fty720在制备治疗行为和运动异常检测标记物中的应用
EP3870292A4 (en)	2018-10-26	2022-11-09	The Research Foundation for The State University of New York	COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
JP7211136B2 (ja) *	2019-02-14	2023-01-24	ニプロ株式会社	錠剤、および、その製造方法
EP3970710A4 (en)	2019-05-13	2023-06-14	VASTHERA Co. Ltd.	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES BY ACTIVATION OF AUTOPHAGY
CN114340606A (zh)	2019-05-15	2022-04-12	瓦西特拉有限公司	包含自噬激活剂作为活性成分的用于预防或治疗心脑血管疾病的组合物
US11080484B1 (en) *	2020-10-08	2021-08-03	Omniscient Neurotechnology Pty Limited	Natural language processing of electronic records

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310524A (en)	1980-04-11	1982-01-12	Richardson-Merrell, Inc.	TCA Composition and method for rapid onset antidepressant therapy
JP2608788B2 (ja)	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
US5114976A (en)	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en)	1989-05-31	1997-01-07	Abbott Laboratories	Dopamine agonists
US5500343A (en)	1990-02-07	1996-03-19	Board Of Regents, The University Of Texas System	Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en)	1992-04-02	1998-07-14	Dynagen, Inc.	Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5663167A (en)	1992-12-09	1997-09-02	The United States Of America As Represented By The Department Of Health And Human Services	Antipsychotic composition and method of treatment
IE930485A1 (en)	1993-06-28	1994-12-28	Hemisphere Ltd	Antidepressant agents with a rapid onset of action
ZA948357B (en)	1994-06-16	1996-04-24	Lilly Co Eli	Potentiation of drug response
CZ198498A3 (cs)	1995-12-22	1999-03-17	Eli Lilly And Company	Použití 2-methyl-4-(4-methyl)-piperazinyl)-10H-thieno[2,3b][1,5]benzodiazepinu
CN1494907A (zh)	1996-03-25	2004-05-12		治疗疼痛的药物组合物
WO1997035584A1 (en)	1996-03-25	1997-10-02	Eli Lilly And Company	Method for treating pain
US6159963A (en)	1996-03-29	2000-12-12	Eli Lilly And Company	Method for treating substance abuse
IL121076A (en) *	1996-06-19	2000-10-31	Akzo Nobel Nv	Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA977967B (en)	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses
ZA982368B (en)	1997-03-27	1998-09-23	Akzo Nobel Nv	New therapeutic combinations
WO1999020279A1 (en)	1997-10-17	1999-04-29	Eli Lilly And Company	Potentiation of pharmaceuticals
GB9801538D0 (en)	1998-01-23	1998-03-25	Merck Sharp & Dohme	Pharmaceutical product
US6228875B1 (en)	1998-04-14	2001-05-08	The General Hospital Corporation	Methods for treating neuropsychiatric disorders
GB2336534A (en)	1998-04-24	1999-10-27	Alec James Coppen	Anti-depressant - Folic Acid Combination
PT1075264E (pt)	1998-05-08	2005-01-31	Upjohn Co	Novas combinacoes farmacologicas de reboxetina e pindolol
US6500827B2 (en)	1998-05-08	2002-12-31	Pharmacia & Upjohn Company	Drug combinations
JP2002515435A (ja)	1998-05-21	2002-05-28	イーライ・リリー・アンド・カンパニー	鬱病処置のための組合せ治療
US6960577B2 (en)	1998-05-22	2005-11-01	Eli Lilly And Company	Combination therapy for treatment of refractory depression
ID26861A (id)	1998-05-22	2001-02-15	Lilly Co Eli	Terapi gabungan untuk pengobatan depresi refaktori
NZ507981A (en)	1998-05-29	2003-10-31	Lilly Co Eli	Combination therapy for treatment of bipolar disorders
US20030027817A1 (en)	1998-05-29	2003-02-06	Tollefson Gary Dennis	Combination therapy for treatment of bipolar disorders
US6420349B1 (en)	1998-08-24	2002-07-16	Bristol-Myers Squibb Company	Isoxazolinone antibacterial agents
DE69912635T2 (de)	1998-11-23	2004-05-13	Sepracor Inc., Marlborough	Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
ATE286398T1 (de)	1998-11-23	2005-01-15	Sepracor Inc	Desmethylolanzapine enthaltende zusammensetzungen und verfahren
WO2000030648A1 (en)	1998-11-23	2000-06-02	Sepracor Inc.	2-hydroxymethylolanzapine compositions and methods
WO2000054764A2 (en)	1999-03-18	2000-09-21	Children's Hospital Research Foundation	A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
EP1165083A2 (en)	1999-04-06	2002-01-02	Sepracor Inc.	Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
US6281207B1 (en)	1999-09-15	2001-08-28	Reed Richter	Treatment of movement disorders by administration of mirtazapine
US6572890B2 (en)	2000-01-13	2003-06-03	Osmotica Corp.	Osmotic device containing venlafaxine and an anti-psychotic agent
US6599532B2 (en)	2000-01-13	2003-07-29	Osmotica Corp.	Osmotic device containing alprazolam and an antipsychotic agent
US6322503B1 (en)	2000-02-17	2001-11-27	G. Roger Sparhawk, Jr.	Method of diagnosing, tracking, and treating depression
DE10018834A1 (de)	2000-04-15	2001-10-25	Lohmann Therapie Syst Lts	Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
JP2004517112A (ja) *	2001-01-02	2004-06-10	ファルマシア・アンド・アップジョン・カンパニー	新規薬物コンビネーション
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
US20020123490A1 (en)	2001-03-01	2002-09-05	Pfizer Inc.	Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
CA2440374A1 (en)	2001-03-14	2002-09-19	Takayuki Maruyama	A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient
WO2002085839A1 (en)	2001-04-19	2002-10-31	Warner-Lambert Company Llc	Fused bicyclic or tricyclic amino acids
WO2002087590A1 (en)	2001-04-26	2002-11-07	Ortho-Mcneil Pharmaceutical, Inc.	Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
DE10129320A1 (de)	2001-06-19	2003-04-10	Norbert Mueller	Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US6582737B2 (en)	2001-09-25	2003-06-24	Peirce Management, Llc	Pharmaceutical composition containing two active ingredients for smoking cessation
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MXPA04007752A (es)	2002-02-08	2005-06-17	Abbott Lab	Terapia de combinacion para tratamiento de esquizofrenia.
EP1336406A1 (en)	2002-02-14	2003-08-20	Solvay Pharmaceuticals B.V.	Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
AU2003227521A1 (en)	2002-05-30	2003-12-19	Neurosearch A/S	Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
US20040127489A1 (en)	2002-07-29	2004-07-01	David Pickar	Novel antipsychotic combination therapies and compositions useful therein
EP1551393A4 (en)	2002-07-30	2010-06-16	Peter Migaly	COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US20040132826A1 (en)	2002-10-25	2004-07-08	Collegium Pharmaceutical, Inc.	Modified release compositions of milnacipran
CA2503121A1 (en)	2002-10-25	2004-05-13	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
MXPA05012538A (es)	2003-05-23	2006-02-22	Otsuka Pharma Co Ltd	Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo.
EP1667686A1 (en)	2003-09-09	2006-06-14	Pfizer Products Inc.	Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
US20050250803A1 (en)	2003-11-26	2005-11-10	Pfizer Inc	Combination of dopamine agonists and monoamine reuptake inhibitors
EP1713486A4 (en)	2003-12-02	2009-04-29	Sheldon Leslie James	COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY

2003
- 2003-12-25 NZ NZ556779A patent/NZ556779A/en not_active IP Right Cessation
- 2003-12-25 AT AT03786308T patent/ATE376419T1/de active
- 2003-12-25 CN CN2003801061036A patent/CN1726039B/zh not_active Expired - Fee Related
- 2003-12-25 WO PCT/JP2003/016724 patent/WO2004060374A1/en not_active Ceased
- 2003-12-25 BR BR0317771-8A patent/BR0317771A/pt active Search and Examination
- 2003-12-25 EP EP06017539A patent/EP1723957A3/en not_active Withdrawn
- 2003-12-25 DE DE60317098T patent/DE60317098T2/de not_active Expired - Lifetime
- 2003-12-25 RU RU2005123808/15A patent/RU2356554C2/ru not_active IP Right Cessation
- 2003-12-25 CN CN2007100016207A patent/CN1989968B/zh not_active Expired - Fee Related
- 2003-12-25 SI SI200331078T patent/SI1575590T1/sl unknown
- 2003-12-25 CA CA2511619A patent/CA2511619C/en not_active Expired - Lifetime
- 2003-12-25 KR KR1020077017722A patent/KR100858852B1/ko not_active Expired - Fee Related
- 2003-12-25 NZ NZ540054A patent/NZ540054A/en not_active IP Right Cessation
- 2003-12-25 AU AU2003295235A patent/AU2003295235B2/en not_active Ceased
- 2003-12-25 EP EP03786308A patent/EP1575590B1/en not_active Expired - Lifetime
- 2003-12-25 PT PT03786308T patent/PT1575590E/pt unknown
- 2003-12-25 ES ES03786308T patent/ES2295677T3/es not_active Expired - Lifetime
- 2003-12-25 MX MXPA05006857A patent/MXPA05006857A/es active IP Right Grant
- 2003-12-25 KR KR1020057012073A patent/KR100842694B1/ko not_active Expired - Lifetime
- 2003-12-25 PL PL378214A patent/PL211975B1/pl unknown
- 2003-12-25 DK DK03786308T patent/DK1575590T3/da active
- 2003-12-26 JP JP2003433429A patent/JP4284524B2/ja not_active Expired - Lifetime
2004
- 2004-01-05 PE PE2004000001A patent/PE20040923A1/es not_active Application Discontinuation
2005
- 2005-05-12 NO NO20052359A patent/NO333291B1/no not_active IP Right Cessation
- 2005-05-13 ZA ZA200503873A patent/ZA200503873B/en unknown
- 2005-06-21 EC EC2005005885A patent/ECSP055885A/es unknown
- 2005-06-23 IL IL169358A patent/IL169358A/en not_active IP Right Cessation
2007
- 2007-11-08 CY CY20071101436T patent/CY1108060T1/el unknown
2008
- 2008-07-29 RU RU2008131331/15A patent/RU2389490C2/ru not_active IP Right Cessation
- 2008-12-19 MY MYPI20085175 patent/MY152919A/en unknown
2014
- 2014-04-15 US US14/252,907 patent/US9387182B2/en not_active Expired - Fee Related
2016
- 2016-06-08 US US15/176,464 patent/US9694009B2/en not_active Expired - Fee Related
2017
- 2017-05-25 US US15/604,720 patent/US20170258788A1/en not_active Abandoned
2019
- 2019-01-08 US US16/242,315 patent/US20190151308A1/en not_active Abandoned
- 2019-10-28 US US16/664,984 patent/US20200289501A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20050085906A (ko)	2005-08-29
US20190151308A1 (en)	2019-05-23
JP4284524B2 (ja)	2009-06-24
ATE376419T1 (de)	2007-11-15
KR100858852B1 (ko)	2008-09-17
EP1575590B1 (en)	2007-10-24
NZ556779A (en)	2008-12-24
DE60317098T2 (de)	2008-08-07
KR20070093001A (ko)	2007-09-14
US20170258788A1 (en)	2017-09-14
ECSP055885A (es)	2005-11-22
EP1723957A3 (en)	2013-01-23
CA2511619A1 (en)	2004-07-22
RU2356554C2 (ru)	2009-05-27
RU2389490C2 (ru)	2010-05-20
BR0317771A (pt)	2005-11-22
MXPA05006857A (es)	2005-08-18
WO2004060374A1 (en)	2004-07-22
AU2003295235B2 (en)	2008-06-19
EP1723957A2 (en)	2006-11-22
NO333291B1 (no)	2013-04-29
MY152919A (en)	2014-12-15
CN1989968B (zh)	2011-05-11
ZA200503873B (en)	2006-08-30
CN1726039B (zh)	2010-08-18
HK1082411A1 (zh)	2006-06-09
US9387182B2 (en)	2016-07-12
NZ540054A (en)	2007-09-28
PL211975B1 (pl)	2012-07-31
CA2511619C (en)	2011-07-12
NO20052359D0 (no)	2005-05-12
SI1575590T1 (sl)	2008-04-30
PT1575590E (pt)	2007-12-06
IL169358A0 (en)	2007-07-04
US20200289501A1 (en)	2020-09-17
JP2004217650A (ja)	2004-08-05
KR100842694B1 (ko)	2008-07-01
NO20052359L (no)	2005-07-18
HK1101550A1 (en)	2007-10-18
ES2295677T3 (es)	2008-04-16
HK1145291A1 (en)	2011-04-15
PE20040923A1 (es)	2005-01-22
CY1108060T1 (el)	2014-02-12
CN1989968A (zh)	2007-07-04
US20140221388A1 (en)	2014-08-07
DK1575590T3 (da)	2008-02-11
EP1575590A1 (en)	2005-09-21
CN1726039A (zh)	2006-01-25
DE60317098D1 (de)	2007-12-06
US9694009B2 (en)	2017-07-04
RU2005123808A (ru)	2006-02-20
US20160310489A1 (en)	2016-10-27
RU2008131331A (ru)	2010-02-10
IL169358A (en)	2013-04-30
AU2003295235A1 (en)	2004-07-29

Legal Events

Date	Code	Title	Description
2012-12-31	RECP	Rectifications of patent specification

Publication	Publication Date	Title
MY152919A (en)	2014-12-15	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
WO2002053140A3 (en)	2002-10-24	New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
MY133238A (en)	2007-10-31	Monoamine reuptake inhibitors for treatment for cns disorders
BR0316535A (pt)	2005-10-04	Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina
CY1112932T1 (el)	2016-04-13	Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
WO2004010932A3 (en)	2004-07-22	Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AR098599A2 (es)	2016-06-01	Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo
BR0306147A (pt)	2004-10-19	Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição
EP1254668A3 (en)	2003-01-02	Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
WO2004052858A3 (en)	2004-08-12	Inhibitors of monoamine uptake
WO2004100939B1 (en)	2007-03-01	Combination of the analeptic modafinil and an antidepressant for the treatment of depression
WO2004100937B1 (en)	2006-12-21	Combination of the analeptic modafinil and an antidepressant for the treatment of depression
CA2428511A1 (en)	2002-05-23	Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors
BRPI0413750A (pt)	2006-10-24	uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
IL156203A0 (en)	2003-12-23	Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
MXPA06002778A (es)	2006-06-14	Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
MY141048A (en)	2010-02-25	Morpholine derivatives as norepinephrine reuptake inhibitors
WO2024259343A3 (en)	2025-02-20	New formulations for mental disorders or mental enhancement
SE9803155D0 (sv)	1998-09-16	A new composition
Soomro	2002	Sertraline reduced patient dropout rates and acute exacerbation of symptoms in obsessive compulsive disorder
Paykel	1995	" Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression": Erratum.
BRPI0413749A (pt)	2006-10-24	uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit
BRPI0415280A (pt)	2006-12-19	métodos para o tratamento de sintomas vasomotores
TW200504016A (en)	2005-02-01	Inhibitors of monoamine uptake